Información de Uniqure NV, dividendo de Uniqure NV, actividades de los accionistas y más

Más Datos de Uniqure NV Compañía

Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.

Información de Uniqure NV



Símbolo de cotizaciónQURE

Nombre de la empresaUniqure NV

Fecha de salida a bolsaFeb 05, 2014

Director ejecutivoMr. Matthew (Matt) Kapusta, CPA

Número de empleados209

Tipo de seguridadOrdinary Share

Fin del año fiscalFeb 05

DirecciónPaasheuvelweg 25a

CiudadAMSTERDAM

Bolsa de valoresNASDAQ Global Select Consolidated

PaísNetherlands

Código postal1105 BP

Teléfono31202406000

Sitio Webhttps://www.uniqure.com/

Símbolo de cotizaciónQURE

Fecha de salida a bolsaFeb 05, 2014

Director ejecutivoMr. Matthew (Matt) Kapusta, CPA

Ejecutivos de Uniqure NV



Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Mr. Christian Klemt, CPA

Chief Financial Officer

99.26K

--

Walid Abi-Saab

Chief Medical Officer

34.63K

-4.06%

Dr. Robert Gut, M.D., Ph.D.

Non-Executive Director

32.06K

-32.72%

Mr. Madhavan (Madhu) Balachandran

Non-Executive Independent Director

29.62K

+24.66%

Dr. Jeremy P. Springhorn, Ph.D.

Non-Executive Independent Director

29.61K

+24.66%

Dr. Leonard E. Post, Ph.D.

Non-Executive Independent Director

21.86K

+36.61%

Ms. Rachelle Suzanne Jacques

Non-Executive Independent Director

20.27K

+40.66%

Dr. Jeannette Potts, J.D., Ph.D.

Chief Legal and Compliance Officer and Corporate Secretary

15.67K

-22.96%

Mr. Jack L. Kaye, CPA

Non-Executive Independent Director

--

Mr. David Meek

Non-Executive Independent Chairman of the Board

--

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Mr. Christian Klemt, CPA

Chief Financial Officer

99.26K

--

Walid Abi-Saab

Chief Medical Officer

34.63K

-4.06%

Dr. Robert Gut, M.D., Ph.D.

Non-Executive Director

32.06K

-32.72%

Mr. Madhavan (Madhu) Balachandran

Non-Executive Independent Director

29.62K

+24.66%

Dr. Jeremy P. Springhorn, Ph.D.

Non-Executive Independent Director

29.61K

+24.66%

Dr. Leonard E. Post, Ph.D.

Non-Executive Independent Director

21.86K

+36.61%

Desglose de ingresos

Sin datos

Sin datos

Por negocio

Por región

Sin datos

Estadísticas de accionistas

Actualizado: sáb., 8 de nov

Accionistas

Tipos de accionistas

Accionistas

Proporción

RTW Investments L.P.

8.28%

EcoR1 Capital, LLC

6.40%

Vestal Point Capital, LP

5.94%

Avoro Capital Advisors LLC

5.82%

abrdn Inc.

4.72%

Otro

68.84%

Accionistas

Proporción

RTW Investments L.P.

8.28%

EcoR1 Capital, LLC

6.40%

Vestal Point Capital, LP

5.94%

Avoro Capital Advisors LLC

5.82%

abrdn Inc.

4.72%

Otro

68.84%

Tipos de accionistas

Accionistas

Proporción

Investment Advisor/Hedge Fund

45.59%

Hedge Fund

18.44%

Investment Advisor

14.82%

Research Firm

6.51%

Corporation

3.88%

Venture Capital

3.21%

Individual Investor

1.50%

Private Equity

0.98%

Bank and Trust

0.24%

Otro

4.83%

Participación institucional



Actualizado: mié., 1 de oct

Periodo del informe

Número de instituciones

Acciones mantenidas

Proporción

Cambio

2025Q3

368

55.15M

89.53%

-7.50M

2025Q2

396

55.26M

101.06%

-1.58M

2025Q1

429

55.29M

101.00%

-4.83M

2024Q4

431

46.57M

86.23%

-10.92M

2024Q3

431

43.93M

89.29%

-10.96M

2024Q2

435

37.07M

76.08%

-15.19M

2024Q1

449

38.56M

80.27%

-17.69M

2023Q4

454

43.54M

90.77%

-8.61M

2023Q3

462

41.52M

86.64%

-16.34M

2023Q2

452

41.43M

87.10%

-18.53M

Actividad de los accionistas



Nombre

Acciones mantenidas

Proporción

Cambio

Cambio %

Fecha

RTW Investments L.P.

5.16M

8.37%

+892.80K

+20.93%

Jun 30, 2025

EcoR1 Capital, LLC

3.99M

6.48%

--

Jun 30, 2025

Vestal Point Capital, LP

3.70M

6.01%

-1.09M

-22.80%

Jun 30, 2025

Avoro Capital Advisors LLC

3.63M

5.88%

+1.45M

+66.67%

Jun 30, 2025

abrdn Inc.

2.75M

4.47%

+535.16K

+24.15%

Jun 30, 2025

Bristol Myers Squibb

2.39M

3.88%

--

Sep 30, 2024

Jefferies LLC

2.10M

3.4%

+2.10M

--

Jun 30, 2025

Nantahala Capital Management, LLC

2.05M

3.33%

-704.11K

-25.55%

Jun 30, 2025

Franklin Advisers, Inc.

1.61M

2.61%

-382.31K

-19.23%

Jun 30, 2025

Two Sigma Investments, LP

1.60M

2.6%

+15.67K

+0.99%

Jun 30, 2025

ETFs relacionados



Actualizado: jue., 6 de nov

Nombre

Proporción

WisdomTree BioRevolution Fund

4.09%

Global X Genomics & Biotechnology ETF

3.36%

Virtus LifeSci Biotech Clinical Trials ETF

2.63%

Invesco NASDAQ Future Gen 200 ETF

1.73%

SPDR S&P Biotech ETF

1.24%

Alger Mid Cap 40 ETF

1.07%

Tema Heart & Health ETF

0.73%

Direxion Daily S&P Biotech Bull 3X Shares

0.65%

Harbor Health Care ETF

0.6%

Invesco Nasdaq Biotechnology ETF

0.34%

WisdomTree BioRevolution Fund

Proporción4.09%

Global X Genomics & Biotechnology ETF

Proporción3.36%

Virtus LifeSci Biotech Clinical Trials ETF

Proporción2.63%

Invesco NASDAQ Future Gen 200 ETF

Proporción1.73%

SPDR S&P Biotech ETF

Proporción1.24%

Alger Mid Cap 40 ETF

Proporción1.07%

Tema Heart & Health ETF

Proporción0.73%

Direxion Daily S&P Biotech Bull 3X Shares

Proporción0.65%

Harbor Health Care ETF

Proporción0.6%

Invesco Nasdaq Biotechnology ETF

Proporción0.34%

Dividendos



Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.

Fecha

Dividendos

Fecha de registro

Fecha de pago

Fecha ex-dividendo

Sin datos

División de acciones



Fecha

Tipo

Relación

Sin datos

Fecha

Tipo

Relación

Sin datos